Special Issue "Cancer Care during COVID-19 Pandemic"
Deadline for manuscript submissions: 31 August 2021.
The COVID-19 pandemic is an unprecedented global event in modern medical history that has resulted in overwhelmed health care systems in many countries. As of the end of 2020, it has infected more than 80 million people and has taken the lives of about 2 million people. Cancer patients are particularly at higher risk of severe COVID-19 infection. In response to the challenges related to the COVID-19 outbreak, cancer care facilities and jurisdictions have rapidly adapted and modified their services to sustain safe cancer care, including the implementation of telemedicine services and virtual care. However, due to overwhelmed health care systems in several jurisdictions, there have been delays in oncologic surgery, (neo)adjuvant therapy or definite chemoradiation that could result in inferior outcomes. Experience of treating cancer patients during this pandemic will likely have much lasting effect on cancer care. Primary prevention with vaccine is one of the most effective interventions to reduce COVID-19 infection and morbidities and mortality associated with the disease. Currently, there are more than 50 COVID-19 vaccine candidates in clinical trials and a few of them have received approval for their use in a healthy population.
In response to COVID-related challenges in cancer patient care, Current Oncology plans to publish a Special Issue on COVID-19. We are pleased to invite you to make contribution in the Special Issue on COVID-19 and Cancer care. This issue aims to publish original articles and systemic reviews addressing the impact of the COVID19 pandemic on the continuum of cancer care, including cancer screening, diagnostics, therapeutics, surveillance, and supportive care, cancer outcomes, and the mental health of cancer patients, as well as research into the COVID-19 vaccine in cancer patients. I look forward to receiving your contributions.
Prof. Dr. Shahid Ahmed
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- corona virus
- cancer care
- cancer treatment
- COVID-19 vaccine
- mental health
- cancer outcomes
- cancer screening
- virtual care